Drug intelligence / Profile preview

Qilong Tongshen Granules

Development stage: Unknown
Lead developer: Shanxi Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Qilong Tongshen Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Shanxi Hospital of Traditional Chinese Medicine. It is primarily investigated for the treatment of idiopathic membranous nephropathy (IMN), a common cause of nephrotic syndrome in adults. The formulation's name, 'Qilong', typically refers to its primary components, *Astragalus membranaceus* (Huangqi) and *Lumbricus* (Dilong), which are used in TCM to tonify Qi and dredge the kidney collaterals. In clinical research, it is evaluated as part of an integrative medicine regimen alongside standard immunosuppressants like cyclophosphamide, cyclosporine, or tacrolimus to optimize treatment outcomes for IMN.

Other names: Qi Long Tong Shen Ke Li芪龙通肾颗粒

Beyond the preview

Go deeper on Qilong Tongshen Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qilong Tongshen Granules.

Explore the full profile